Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas of disease.  | The companies said they will work together to train ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as the world’s first transfemoral transcatheter mitral valve replacement ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans to seek accelerated FDA approval in the first half of next year.

“We were probably one of the lucky few that was able to go out last fall and have such a strong and successful IPO,” Bicara ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and stopping clinical development of its lead program to hunker down and seek ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...

Having picked up a pipeline of oncology drugs as part of a merger last year, NAYA Biosciences is reverting back to its original focus of fertility and ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue ...

CTI grew from a Cincinnati startup to a global leader in clinical research. CEO Tim Schroder shares insights on its success ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

The U.K. is rolling out new regulations meant to reduce red tape for clinical studies and boost the nation’s role in international trials.

| Discover how AI and RWD are transforming drug development by optimizing clinical trial protocols, enhancing recruitment, ...